Nervgen Pharma Corp (NGENF)

$3.29 -0.09 (-2.56%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 149,289
Avg Vol 112,470
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 94%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
dave871
dave871 Oct. 9 at 7:56 PM
$NGENF
0 · Reply
o63l0
o63l0 Oct. 9 at 6:40 PM
$NGENF hi guys, I hope you doing well. Honestly? This drug NVG-291 have potential to do a new world tv "serie" Walking Dead with spinal cord injury community, but is better than nothing to try to leave the bed and the wheelchair.
0 · Reply
o63l0
o63l0 Oct. 9 at 5:27 PM
$NGENF Hello Commissioner, I’ve been following the progress of NervGen Pharma’s NVG291 program with great interest. The potential of this therapy for neural repair seems remarkable, and I hope the FDA continues to give innovative treatments like this thoughtful consideration. Thank you for your continued commitment to advancing science and patient well-being.
0 · Reply
CCbank
CCbank Oct. 9 at 3:52 PM
$NGENF give me some news.
1 · Reply
1_sitting_bull
1_sitting_bull Oct. 9 at 10:51 AM
$NGENF
0 · Reply
Eldorado_Toole
Eldorado_Toole Oct. 9 at 3:14 AM
$NGENF "Why This Could Be a Turning Point in Neurorepair" Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA https://afshine.substack.com/p/from-silence-to-steps-how-an-experimental
0 · Reply
Eldorado_Toole
Eldorado_Toole Oct. 9 at 1:16 AM
$NGENF CEO Adam Rogers, MD, will join the #BioFuture2025 panel next week Our CEO Adam Rogers, MD, will join the #BioFuture2025 panel, “Rewiring Minds: Breakthroughs in Brain & CNS Health,” exploring how advances in neuroscience are transforming healthcare.Oct 13 |11 AM |NYC https://biofuture.com #SCI #SpinalCordInjury #CNS #Biotech https://x.com/NervgenP/status/1975981515029844233
1 · Reply
shopno
shopno Oct. 8 at 8:55 PM
$NGENF To add further, my prediction is NGENF would get acquired even before full scale of chronic and acute SCI rollout. From a long investor perspective, NGENF should first ramp sales to treat 5-10k patients a year that potentially can bring $1-2B revenue a year ($200K/patient). Market would push the valuation to $5-10B, and a high-premium implies $10-20B BO. Achievable whin 3-4 years post-FDA approval. First NGENF needs AA, and a lot of media coverage and active engagement with SCI community.
1 · Reply
CCbank
CCbank Oct. 8 at 6:39 PM
$NGENF this needs to be out of otc market... need to be more available. anyone knows where u can buy this stock other than schwab???
6 · Reply
Sanzoo
Sanzoo Oct. 8 at 5:45 PM
$NGENF $150 Is it possible? After approval
4 · Reply
Latest News on NGENF
No data available.
dave871
dave871 Oct. 9 at 7:56 PM
$NGENF
0 · Reply
o63l0
o63l0 Oct. 9 at 6:40 PM
$NGENF hi guys, I hope you doing well. Honestly? This drug NVG-291 have potential to do a new world tv "serie" Walking Dead with spinal cord injury community, but is better than nothing to try to leave the bed and the wheelchair.
0 · Reply
o63l0
o63l0 Oct. 9 at 5:27 PM
$NGENF Hello Commissioner, I’ve been following the progress of NervGen Pharma’s NVG291 program with great interest. The potential of this therapy for neural repair seems remarkable, and I hope the FDA continues to give innovative treatments like this thoughtful consideration. Thank you for your continued commitment to advancing science and patient well-being.
0 · Reply
CCbank
CCbank Oct. 9 at 3:52 PM
$NGENF give me some news.
1 · Reply
1_sitting_bull
1_sitting_bull Oct. 9 at 10:51 AM
$NGENF
0 · Reply
Eldorado_Toole
Eldorado_Toole Oct. 9 at 3:14 AM
$NGENF "Why This Could Be a Turning Point in Neurorepair" Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA https://afshine.substack.com/p/from-silence-to-steps-how-an-experimental
0 · Reply
Eldorado_Toole
Eldorado_Toole Oct. 9 at 1:16 AM
$NGENF CEO Adam Rogers, MD, will join the #BioFuture2025 panel next week Our CEO Adam Rogers, MD, will join the #BioFuture2025 panel, “Rewiring Minds: Breakthroughs in Brain & CNS Health,” exploring how advances in neuroscience are transforming healthcare.Oct 13 |11 AM |NYC https://biofuture.com #SCI #SpinalCordInjury #CNS #Biotech https://x.com/NervgenP/status/1975981515029844233
1 · Reply
shopno
shopno Oct. 8 at 8:55 PM
$NGENF To add further, my prediction is NGENF would get acquired even before full scale of chronic and acute SCI rollout. From a long investor perspective, NGENF should first ramp sales to treat 5-10k patients a year that potentially can bring $1-2B revenue a year ($200K/patient). Market would push the valuation to $5-10B, and a high-premium implies $10-20B BO. Achievable whin 3-4 years post-FDA approval. First NGENF needs AA, and a lot of media coverage and active engagement with SCI community.
1 · Reply
CCbank
CCbank Oct. 8 at 6:39 PM
$NGENF this needs to be out of otc market... need to be more available. anyone knows where u can buy this stock other than schwab???
6 · Reply
Sanzoo
Sanzoo Oct. 8 at 5:45 PM
$NGENF $150 Is it possible? After approval
4 · Reply
CCbank
CCbank Oct. 8 at 5:12 PM
$NGENF did something happened?
3 · Reply
Rexpower
Rexpower Oct. 8 at 4:44 PM
$NGENF Larry being able to stand on 1 foot for 30 seconds is quite astonishing. Consider how challenging that is. The feedback to and from the brain to all the intricate muscles throughout the body in order to balance on one foot. Added he couldnt even do it for a second a few weeks ago. I don't want to call it a miracle but it is amazing. I guess I can say it's a miracle of science.
2 · Reply
cranberry1
cranberry1 Oct. 8 at 12:37 AM
$NGENF this thing seems primed for a buyout from the big boys.
2 · Reply
Nervous88
Nervous88 Oct. 7 at 9:37 PM
$NGENF A nice write up https://afshine.substack.com/p/from-silence-to-steps-how-an-experimental?utm_source=%2Fsearch%2Fnervgen&utm_medium=reader2
2 · Reply
Tarquinjones
Tarquinjones Oct. 7 at 9:33 PM
$NGENF tell a friend to tell a friend
0 · Reply
CCbank
CCbank Oct. 7 at 2:09 PM
$NGENF i thought this stock went crazy today. but i looked at 3 month chart. lol. have a good day guys
3 · Reply
Buckeye250
Buckeye250 Oct. 7 at 12:02 PM
$NGENF Even higher quality videos of Clay than the TV segment. At 930k views and counting… https://www.facebook.com/share/r/17GTFpqmKn/?mibextid=wwXIfr
3 · Reply
MarianoItaliano
MarianoItaliano Oct. 7 at 10:13 AM
$NGENF I’m not even joking here, with all the neurological diseases which can at least partly benefit from nvg-291 or nvg-300, this could be even one of the first 1T$ biotech companies. Knowing about them and not giving them a chance by betting at least 100 bucks is kinda nuts if you ask me https://stkt.co/Xk30TGZw
1 · Reply
MarianoItaliano
MarianoItaliano Oct. 6 at 8:58 PM
$SPRB is a nice teaser of what can happen to $NGENF if AA is given by FDA
6 · Reply
CCbank
CCbank Oct. 6 at 7:31 PM
$NGENF it should be higher today with this volume. but wat is going on
0 · Reply
rwelsh633
rwelsh633 Oct. 6 at 5:54 PM
$NGENF More news coverage!
4 · Reply
Rolo609
Rolo609 Oct. 6 at 2:23 PM
$NGENF I'm in at 3$. You got my attention with paralyzed man walks again. $APLD $NBIS turning up that slot machine today. $ACHR looking good as well. Happy Monday traders!!
3 · Reply